Table Of Contents:

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	22
2.2 Major Growth Drivers	24
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of North America Market by Offering	41
3.1 Market Overview by Offering	41
3.2 Services	43
3.3 Test Kits & Consumables	44
4 Segmentation of North America Market by Application	45
4.1 Market Overview by Application	45
4.2 Non-Hodgkin’s Lymphoma (NHL)	47
4.2.1 DLBCL	49
4.2.2 Marginal Zone Lymphoma	50
4.2.3 Follicular Lymphoma	51
4.2.4 Peripheral T-cell Lymphoma	52
4.2.5 Mantle Cell Lymphoma	53
4.2.6 Other NHLs	54
4.3 Multiple Myeloma (MM)	55
4.4 Acute Lymphoblastic Leukemia (ALL)	56
4.5 Chronic Lymphoblastic Leukemia (CLL)	57
4.6 Acute Myeloid Leukemia (AML)	58
4.7 Chronic Myeloid Leukemia (CML)	59
4.8 Hodgkin’s Lymphoma (HL)	60
4.9 Solid Tumor	61
4.10 Other Applications	62
5 Segmentation of North America Market by Technology	63
5.1 Market Overview by Technology	63
5.2 Flow Cytometry	65
5.3 Polymerase Chain Reaction (PCR)	66
5.4 Next-Generation Sequencing (NGS)	67
5.5 Other Technologies	68
6 Segmentation of North America Market by End User	69
6.1 Market Overview by End User	69
6.2 Hospitals and Clinics	71
6.3 Research Institutions	72
6.4 Diagnostic Laboratories	73
6.5 Other End Users	74
7 North America Market 2021-2031 by Country	75
7.1 Overview of North America Market	75
7.2 U.S.	78
7.3 Canada	81
7.4 Mexico	83
8 Competitive Landscape	85
8.1 Overview of Key Vendors	85
8.2 New Product Launch, Partnership, Investment, and M&A	89
8.3 Company Profiles	90
Adaptive Biotechnologies Corporation	90
ArcherDX, Inc. (Invitae Corporation)	92
Arup Laboratories	93
Asuragen Inc.	94
Bio-Rad Laboratories, Inc.	95
Cergentis B.V.	96
Guardant Health	97
ICON plc	98
Inivata Ltd.	99
Invivoscribe, Inc.	100
Laboratory Corporation of America Holdings	101
Mission Bio, Inc.	102
Natera, Inc.	103
NeoGenomics Laboratories, Inc.	104
Opko Health, Inc.	105
Quest Diagnostics Incorporated	106
Sysmex Corporation	107
RELATED REPORTS	108

List of Tables:

Table 1.  Snapshot of North America Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031	17
Table 2. World Economic Outlook, 2021-2031	21
Table 3. World Health Spending by Region, $ bn, 2013-2020	29
Table 4.  Main Product Trends and Market Opportunities in North America Minimal Residual Disease Testing Market	33
Table 5. North America Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn	41
Table 6. North America Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	45
Table 7. North America Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn	48
Table 8. North America Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	63
Table 9. Main Vendors and Products of Flow Cytometry Technology	65
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology	66
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology	67
Table 12. North America Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	69
Table 13. North America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn	76
Table 14. U.S. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	80
Table 15. U.S. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	80
Table 16. U.S. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	80
Table 17. Canada Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	82
Table 18. Canada Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	82
Table 19. Canada Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	82
Table 20. Mexico Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn	84
Table 21. Mexico Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn	84
Table 22. Mexico Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn	84
Table 23. Breakdown of World Market by Key Vendor, 2021, %	87
Table 24. Approved and Launched MRD Testing Products of Key Vendors	87
Table 25. Adaptive Biotechnologies Corporation: Company Snapshot	90
Table 26. Adaptive Biotechnologies Corporation: Business Segmentation	91
Table 27. Adaptive Biotechnologies Corporation: Product Portfolio	91

List of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031	16
Figure 4. North America Minimal Residual Disease Testing Market, 2021-2031, $ mn	19
Figure 5. Impact of COVID-19 on Business	22
Figure 6. Primary Drivers and Impact Factors of North America Minimal Residual Disease Testing Market	24
Figure 7.  World Number of Deaths from Cancers in 201	27
Figure 8.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	28
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060	28
Figure 10. Primary Restraints and Impact Factors of North America Minimal Residual Disease Testing Market	30
Figure 11. Investment Opportunity Analysis	34
Figure 12. Porter’s Fiver Forces Analysis of North America Minimal Residual Disease Testing Market	37
Figure 13. Breakdown of North America Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue	42
Figure 14. North America Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%)	42
Figure 15. North America Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn	43
Figure 16. North America Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn	44
Figure 17. Breakdown of North America Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue	46
Figure 18. North America Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%)	46
Figure 19. North America Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn	47
Figure 20. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn	49
Figure 21. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn	50
Figure 22. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn	51
Figure 23. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn	52
Figure 24. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn	53
Figure 25. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn	54
Figure 26. North America Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn	55
Figure 27. North America Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn	56
Figure 28. North America Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn	57
Figure 29. North America Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn	58
Figure 30. North America Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn	59
Figure 31. North America Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn	60
Figure 32. North America Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn	61
Figure 33. North America Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn	62
Figure 34. Breakdown of North America Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue	64
Figure 35. North America Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%)	64
Figure 36. North America Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn	65
Figure 37. North America Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn	66
Figure 38. North America Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn	67
Figure 39. North America Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn	68
Figure 40. Breakdown of North America Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue	70
Figure 41. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%)	70
Figure 42. North America Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn	71
Figure 43. North America Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn	72
Figure 44. North America Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn	73
Figure 45. North America Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn	74
Figure 46. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue	76
Figure 47. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)	77
Figure 48. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn	79
Figure 49. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn	81
Figure 50.  Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn	83
Figure 51. Growth Stage of North America Minimal Residual Disease Testing Industry over the Forecast Period	85

Selected Key Players: 
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)